COVID-19 in Hematology Research Grant

The call for LOIs is now closed.

This ad hoc EHA Research Grant call responds to the current COVID-19 pandemic and reflects EHA’s commitment to supporting quality research projects in this area.

The grant is intended for basic, translational or clinical research questions that address:

  • aspects of COVID-19 infection in malignant and benign hematologic disorders OR
  • hematological and immunological manifestations in COVID-19 infection

Amount and duration of the grant

At this stage, no specific budgetary restrictions apply but funding will be in the range of €50.000 – €120.000 for a duration of 1 year.


Collaborative projects are encouraged. Collaborative projects involving research between hematology and other medical disciplines will also be evaluated. If one of the collaborators is outside Europe, at least 50% of the research must be performed in Europe.

How to apply

The call entails a two-step procedure. First to be submitted, a letter of intent (LoI) briefly outlining the scope of the project in no more than 1500 words. LoIs should be structured as follows: Background, Rationale, Aims, Methods, Expected results, and Budget overview. In addition, a concise CV for each PI should also be submitted. These documents should be collated into 1 pdf, named <PI last name.PI first name_PI institute.pdf>, and should be sent to before May 5, 2020 (15:00 CEST).

LOIs will be screened by the EHA’s Fellowships & Grants Committee members and experts in infectious disease for novelty, relevance to the hematology community, feasibility, and accuracy. Highest ranked applicants will then be invited to submit a full proposal by June 2, 2020 (15:00 CEST).

With the help of external reviewers, the F&G committee and the experts in infectious diseases will identify which applications are most promising. The applicants will be interviewed via video conference on June 22, 2020.